Posts for: October, 2014
Last week, an advisory panel to the US Food and Drug Administration unanimously backed the use of Novartis' drug, Cosentyx, as a treatment for plaque-psoriasis. The injectable biologic is a member of a class of drugs known as IL-17 inhibitors, which targers the inflammation-causing protein interleukin-17 (IL-17). This class of drug has shown promising success in the treatment of plaque psoriasis. Although the FDA is not obligated to accept the panel's recommendations, it typically does so.
A new study in the Americal Journal of Public Health found that the rise in melanoma cases over the past 30 years may be atribbuted to social norms. The researchers identified factors that have led to increased UV exposure over the past 100 years. Such factors included clothing styles, travel patterns, and perception of tan skin. For example, when tan skin was at the height of its popularity between the 1940s and 1960s, incidence of melanoma went up 300% in men and 400% in women.